Skip to main content

Table 1 Baseline characteristics of the patients receiving antifungal therapy with an echinocandin according to local guidelines

From: Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU

  Empirical therapy (n = 39) Definite therapy (n = 12) p
Age (years)   65.9 (13.3) 64.6 (17.5) 0.77
Gender (men,%)   25 (64.1) 7 (58.3) 0.72
SAPS II   49.1 (17.1) 49.8 (8.1) 0.89
Admission diagnosis     0.17
  Sepsis (N. [%]) 20 (51.2) 4 (33.3)  
  Respiratory distress (N. [%]) 15 (38.4) 8 (66.6)  
  Other (N. [%]) 4 (10.2) 0 (0)  
Underlying disease(s)   
  Diabetes mellitus (N. [%]) 12 (30.7) 1 (8.3) 0.11
  Cardiac failure (N. [%]) 15 (38.4) 2 (16.6) 0.16
  Chronic lung disease (N. [%]) 12 (30.7) 1 (8.3) 0.11
  Cirrhosis (N. [%]) 5 (12.8) 3 (25) 0.31
  Chronic renal failure (N. [%]) 3 (7.7) 1 (8.3) 0.94
  Cancer (N. [%]) 6 (15.4) 1 (8.3) 0.53
  Hemopathy (N. [%]) 3 (7.7) 0 (0) 0.32
  Immunosuppression (N. [%]) 9 (23.1) 1 (8.3) 0.26
  Transplantation (N. [%]) 3 (7.7) 1 (8.3) 0.94
  1. SAPS II: simplified acute physiologic score II.